Retrospective Evaluation of the Prognostic Value of Histological Growth Pattern in Patients with Colorectal Peritoneal Metastases Undergoing Curative-Intent Cytoreductive Surgery

被引:1
|
作者
Kamdem, Leonel [1 ]
El Asmar, Antoine [1 ]
Demetter, Pieter [2 ]
Zana, Ismael Coulibaly [2 ]
Khaled, Charif [1 ]
Sclafani, Francesco [3 ]
Donckier, Vincent [1 ]
Vermeulen, Peter [4 ]
Liberale, Gabriel [1 ]
机构
[1] Univ Libre Bruxelles, Inst Jules Bordet, Dept Surg, Brussels, Belgium
[2] Univ Libre Bruxelles, Inst Jules Bordet, Dept Pathol, Brussels, Belgium
[3] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med Oncol, Brussels, Belgium
[4] Univ Antwerp, GZA Hosp St Augustinus, Dept Oncol Res, Translat Canc Res Unit, Antwerp, Belgium
关键词
Histological growth patterns; Peritoneal carcinomatosis; Colorectal cancer; Cytoreductive surgery; HIPEC; LIVER METASTASES; CANCER; HIPEC; CARCINOMATOSIS; CENTRALIZATION; CHEMOTHERAPY; DISPARITIES; MANAGEMENT; PREDICTOR; HOSPITALS;
D O I
10.1245/s10434-024-15125-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Two distinct histological growth patterns (HGPs) were described in patients with peritoneal metastasis of colorectal cancer origin (PMCRC) with limited Peritoneal Cancer Index (PCI) <= 6 who did not receive neoadjuvant chemotherapy (NAC) and were treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): pushing HGP (P-HGP) and infiltrating HGP (I-HGP). Patients with dominant P-HGP (>50%) had significantly better disease-free survival (DFS) and overall survival (OS). Objective We aimed to determine whether these previous observations regarding the prognostic value of HGP in patients with PMCRC with low PCI (<= 6) are also valid in all operable patients, regardless of whether they received NAC or not and regardless of PCI score. Methods This was a retrospective study including 76 patients who underwent complete CRS HIPEC for PMCRC between July 2012 and March 2019. In each patient, up to five of the largest excised peritoneal nodules were analyzed for their tumor-to-peritoneum interface. Correlations between NAC, HGP, and prognosis were further explored. Results Thirty-seven patients (49%) had dominant P-HGP and 39 (51%) had dominant I-HGP. On univariate analysis, patients with P-HGP <= 50% had significantly lower OS than those with dominant P-HGP >50% (39 versus 60 months; p=0.014) confirmed on multivariate analysis (hazard ratio 2.4, 95% confidence interval 1.3-4.5; p=0.006). There were no significant associations between NAC and type of HGP. Conclusions This study confirms the prognostic value and reproducibility of the two previously reported HGPs in PMCRC. Dominant P-HGP is associated with better DFS and OS in patients undergoing curative-intent CRS +/- HIPEC compared with I-HGP, independently of the extent of peritoneal disease burden.
引用
收藏
页码:3778 / 3784
页数:7
相关论文
共 50 条
  • [41] Is There a Role for Routine Specialty Palliative Care Consultation in Cancer Patients Undergoing Curative-Intent Surgery?
    DePeralta, Danielle K.
    ANNALS OF SURGERY, 2021, 274 (06) : E651 - E651
  • [42] Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases
    Pollini, Tommaso
    Tran, Thuy
    Wong, Paul
    Adam, Mohamed A.
    Alseidi, Adnan
    Corvera, Carlos
    Hirose, Kenzo
    Nakakura, Eric
    Warren, Robert
    Maker, Vijay K.
    Maker, Ajay V.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 28 (03) : 246 - 251
  • [43] Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases
    Ljunggren, Malin
    Nordenvall, Caroline
    Palmer, Gabriella
    EJSO, 2021, 47 (11): : 2865 - 2872
  • [44] Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
    Dietz, Michelle V.
    Hannink, Gerjon
    Said, Ibrahim
    van der Zant, Femke A.
    van de Vlasakker, Vincent C. J.
    Brandt-Kerkhof, Alexandra R. M.
    Verhoef, Cornelis
    Bremers, Andreas J. A.
    de Wilt, Johannes H. W.
    Hemmer, Patrick H. J.
    de Hingh, Ignace H. J. T.
    de Reuver, Philip R.
    Madsen, Eva V. E.
    EJSO, 2024, 50 (06):
  • [45] Neoadjuvant chemotherapy does not improve survival for patients with high volume colorectal peritoneal metastases undergoing cytoreductive surgery
    Sarofim, Mina
    Wijayawardana, Ruwanthi
    Ahmadi, Nima
    Barat, Shoma
    Liauw, Winston
    Morris, David L.
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [46] Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review
    El-Nakeep, Sarah
    Rashad, Noha
    Oweira, Hani
    Schmidt, Jan
    Helbling, Daniel
    Giryes, Anwar
    Petrausch, Ulf
    Mehrabi, Arianeb
    Decker, Michael
    Abdel-Rahman, Omar
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (03) : 249 - 258
  • [47] Prognostic value of histological growth pattern in patients operated for breast cancer liver metastases
    Bohlok, A.
    Botzenhart, L.
    Lucidi, V.
    Noel, J. C.
    Demetter, P.
    Larsimont, D.
    Donckier, V.
    Vermeulen, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Comparison of Prognostic Scores for Patients with Colorectal Cancer Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Peter H. Cashin
    Wilhelm Graf
    Peter Nygren
    Haile Mahteme
    Annals of Surgical Oncology, 2013, 20 : 4183 - 4189
  • [49] Prognostic value of thrombocytosis in patients undergoing surgery for colorectal cancer with synchronous liver metastases
    Pedrazzani, C.
    Turri, G.
    Mantovani, G.
    Conti, C.
    Ziello, R.
    Conci, S.
    Campagnaro, T.
    Ruzzenente, A.
    Guglielmi, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (12): : 1644 - 1653
  • [50] Prognostic value of thrombocytosis in patients undergoing surgery for colorectal cancer with synchronous liver metastases
    C. Pedrazzani
    G. Turri
    G. Mantovani
    C. Conti
    R. Ziello
    S. Conci
    T. Campagnaro
    A. Ruzzenente
    A. Guglielmi
    Clinical and Translational Oncology, 2019, 21 : 1644 - 1653